3D Medicines (HKSE:01244) EBIT per Share : HK$-2.64 (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines EBIT per Share?

3D Medicines's EBIT per Share for the six months ended in Dec. 2023 was HK$-1.74. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.64.

During the past 3 years, the average EBIT per Share Growth Rate was -12.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for 3D Medicines's EBIT per Share or its related term are showing as below:

HKSE:01244' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -12.7 Med: -12.7 Max: -12.7
Current: -12.7

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of 3D Medicines was -12.70% per year. The lowest was -12.70% per year. And the median was -12.70% per year.

HKSE:01244's 3-Year EBIT Growth Rate is ranked worse than
68.74% of 1302 companies
in the Biotechnology industry
Industry Median: 3.6 vs HKSE:01244: -12.70

3D Medicines's EBIT for the six months ended in Dec. 2023 was HK$-403.1 Mil.

3D Medicines EBIT per Share Historical Data

The historical data trend for 3D Medicines's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines EBIT per Share Chart

3D Medicines Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-2.91

-6.99

-25.75

-2.66

3D Medicines Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial			-	-1.48	-3.17	-0.91	-1.74

3D Medicines EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

3D Medicines's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-606.713	/	228.469
=	-2.66

3D Medicines's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-403.094	/	232.352
=	-1.73

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-2.64

3D Medicines (HKSE:01244) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

3D Medicines EBIT per Share Related Terms

Thank you for viewing the detailed overview of 3D Medicines's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

3D Medicines (HKSE:01244) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN

Website

https://www.3d-medicines.com

3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.

Executives

Gong Zhaolong	2101 Beneficial owner
Zhu Pai	2101 Beneficial owner
Dragon Prosper Holdings Limited	2101 Beneficial owner
Simcere Pharmaceutical Group Limited	2101 Beneficial owner
Gong Zhaolong	2501 Other
Immunal Medixin Us Limited	2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership)	2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd.	2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.)	2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership)	2201 Interest of corporation controlled by you
Zhu Jinqiao	2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines